PFX

PhenixFIN is an internally-managed BDC, and for a BDC the P/E of 20.7 is the wrong lens — the story is asset value. Stockholders' equity of $161M across just ~2.00M shares implies a book/NAV value near $80.50 per share, yet the stock trades at $42.55, roughly 0.53x book. That deep discount is the core of any bull case: it provides a margin of safety, makes the company's buybacks accretive to remaining holders, and gives the board's stated exploration of 'strategic alternatives' (cited repeatedly in the MD&A's forward-looking section) a clear value-unlock path if a sale, liquidation, or wind-down closes the gap. Leverage is modest for a BDC — liabilities/equity of 0.97x sits comfortably inside the 1940 Act's 200% asset-coverage requirement disclosed in Item 1A.

The fundamentals, however, are deteriorating sharply and cap conviction. Net income fell 77.7% to $4.16M (EPS $2.06, down 77.4%), the third straight annual decline from $26.9M in FY2023 to $18.6M in FY2024 to $4.16M now, dragging ROE to just 2.6%. As the MD&A notes, revenue is interest income plus dividends and 'capital gains, if any,' on a portfolio of below-investment-grade loans the filing itself calls 'predominantly speculative' — so reported earnings swing with marks and are not a clean run-rate. More concerning operationally: cash collapsed 89.2% to $7.30M and operating cash flow was -$67.3M, reflecting heavy net investment deployment but leaving thin liquidity, while dividends paid ($2.89M) exceeded GAAP net income's distributable support.